Lupin Limited delivered a strong operational performance in the fourth quarter of FY26, with consolidated net profit rising 88 percent year-on-year to Rs 1,469 crore. The earnings expansion was largely driven by robust growth in the US market, favourable foreign exchange movements, and significant improvement in operating margins.

Revenue from operations rose 32 percent compared with the same period last year to Rs 7,492 crore, indicating broad-based demand momentum across major markets. The company’s US business remained the primary growth engine, with sales from the geography increasing 57 percent year-on-year. The sharp acceleration in the US market comes at a time when several Indian pharmaceutical companies are witnessing recovery in pricing, stronger specialty product contribution, and easing supply chain disruptions after multiple volatile years.

A key highlight of the quarter was margin expansion. Lupin’s EBITDA margin improved sharply to 35.5 percent from 24.8 percent a year ago. The improvement suggests a combination of better product mix, higher utilisation levels, forex benefits, and disciplined cost management. For investors, this is particularly important because profitability expansion in the pharmaceutical sector often has a more durable impact on valuations than one-off revenue spikes.

The company’s latest performance reflects a broader structural shift underway in the Indian pharmaceutical export ecosystem. After years of pricing erosion in the US generics market, companies with strong compliance records, niche product portfolios, and specialty exposure are gradually regaining pricing power and operational stability. Lupin appears to be benefiting from that transition phase.

The US market continues to remain strategically critical for Indian pharmaceutical manufacturers because it contributes significantly to profitability despite regulatory complexities. Strong execution in the region can materially improve earnings quality due to better margins compared with many domestic formulations businesses. Lupin’s quarterly numbers indicate that its product pipeline and market positioning are currently supporting this recovery cycle.

Currency movements also played an important role during the quarter. A favourable forex environment helped support profitability, particularly for export-heavy businesses with substantial dollar-denominated revenue.

However, while forex gains can enhance quarterly earnings, investors generally track whether underlying operational momentum remains sustainable even in the absence of currency support.